Hanmi's Eppe is due this month at 129,800 won wholesale for four weeks, against about 210,000 to 270,000 won for Wegovy and Mounjaro. At the 299,200 won maintenance dose, Seoul Economic Daily puts the gap at 17% to 19%.
Perspective Coverage
3 publishers
- Builder
- Builder 13%
- Operator
- Operator 37%
- Investor
- Investor 50%
Reality
- Evidence55
- Adoption
- Not scored
- Hype gap+35
- Incentives60
- Confidence62
AstraZeneca will pay insitro $40 million up front, with up to about $1.46 billion in milestones to follow, for liver and heart targets. At 2.7% of the disclosed total, the upfront leaves most of the value tied to targets insitro has yet to deliver.
Perspective Coverage
5 publishers
- Builder
- Builder 27%
- Operator
- Operator 26%
- Investor
- Investor 47%
Reality
- Evidence62
- Adoption
- Not scored
- Hype gap+30
- Incentives
- Not scored
- Confidence68
Healthcare led the S&P 500 up 0.33% on Thursday as Treasury yields fell and AI-linked shares sold off. The Labor Department put September producer prices up 1.3% against a 0.6% forecast, yet the 10-year yield's session low was still 5.037%.
Reality
- Evidence72
- Adoption
- Not scored
- Hype gap+15
- Incentives
- Not scored
- Confidence70
Employers start dropping GLP-1 weight-loss coverage a year after widely adding it
Business Group on Health's survey finds at least 10% of employer plans covering GLP-1 weight-loss drugs likely to drop them in 2027. About two-thirds of private employer plans covered them in 2026, and each exit now leaves workers to pay cash or stop.
Reality
- Evidence58
- Adoption60
- Hype gap+15
- Incentives55
- Confidence55
Alight offers employers a fixed-budget alternative to dropping GLP-1 coverage
Alight announced a GLP-1 health reimbursement account on October 13, 2026 that lets employers fund a set budget for the drugs. Business Group on Health found large-employer coverage fell from 72 percent to 60 percent in a year.
Reality
- Evidence55
- Adoption
- Not scored
- Hype gap+10
- Incentives60
- Confidence55
Drugmakers are building addiction and Parkinson's programs on GLP-1 compounds
Lilly's brenipatide, tested for alcohol use disorder, has a half-life of 9-12 days against 5-7 for approved GLP-1 drugs, Nature reported. Kariya has early Parkinson's data on KP405. Baseline plans a phase III of BT-001 in early 2027.
Reality
- Evidence40
- Adoption15
- Hype gap+20
- Incentives35
- Confidence55
GLP-1 drugs outsold generative AI in 2025 on Exponential View's own estimate of AI revenue
Exponential View says GLP-1 sales reached $76 billion in 2025, ahead of its own $63 billion estimate for generative AI. The $13 billion lead rests on that estimate, and the retention studies the piece cites show heavy attrition.
Reality
- Evidence45
- Adoption11
- Hype gap+20
- Incentives40
- Confidence50
Gallup's revised survey finds 11% of US adults taking GLP-1s for weight loss, up from 3% in 2024
Gallup found 11% of US adults now take a GLP-1 for weight loss, up from 3% in 2024. Its survey of 5,065 adults counts users, not spending, so food and insurance planners still need their own dollar figures.
Publishers:news.gallup.com
Reality
- Evidence62
- Adoption11
- Hype gap+10
- Incentives
- Not scored
- Confidence66
Medicaid GLP-1 spending has risen since 2019 although only 13 state programs cover obesity use
KFF counts 13 state Medicaid programs covering GLP-1s for obesity under fee-for-service as of January 2026. Medicaid prescriptions and gross spending on the drugs have risen substantially since 2019, so public use is growing even where obesity coverage is thin.
Publishers:kff.org
Reality
- Evidence58
- Adoption
- Not scored
- Hype gap+25
- Incentives
- Not scored
- Confidence55
Mounjaro at a third of Korea's price draws Koreans to Japanese clinics
Korean customs detected 5,030 illegal obesity-drug imports through August, up from four in 2024, as Koreans fly to Japan for cheaper Mounjaro. Korea's visible answer so far is tighter border checks, with no reported cut to clinic prices for the uninsured drug.
Reality
- Evidence55
- Adoption30
- Hype gap+20
- Incentives
- Not scored
- Confidence55
Korea's regulator approved Hanmi Pharmaceutical's efpeglenatide, the first homegrown GLP-1 obesity drug, after patients lost 9.02% of body weight in 40 weeks. That is less than Wegovy and Mounjaro showed in longer trials, so Hanmi's case rests on milder side effects and a price for long-term patients that it has not yet set.
Reality
- Evidence60
- Adoption8
- Hype gap+15
- Incentives60
- Confidence58
Novo Nordisk and Eli Lilly say patients on their GLP-1 drugs measured two to three years younger on molecular aging clocks than those on placebo. The size of that drop swings with which clock is used and which organ it reads.
Reality
- Evidence45
- Adoption60
- Hype gap+35
- Incentives80
- Confidence50
Price decides whether Hanmi's Eppe takes share from Mounjaro and Wegovy
Hanmi Pharmaceutical's Eppe, Korea's first home-grown GLP-1 obesity drug, is approved and expected to launch at about half Wegovy's 200,000-won-plus price. Its trial weight loss trails both incumbents, so the launch price will set how much of a Mounjaro-dominated market it can reach.
Reality
- Evidence55
- Adoption8
- Hype gap+10
- Incentives40
- Confidence50
Alphabet's Isomorphic Labs is in funding talks at a $40 billion valuation. Crypto Briefing put its prior mark near $17.5 billion, so the ask more than doubles the price of a drug designer that has yet to dose a patient.
Perspective Coverage
6 publishers
- Builder
- Builder 26%
- Operator
- Operator 17%
- Investor
- Investor 57%
Reality
- Evidence55
- Adoption25
- Hype gap+45
- Incentives55
- Confidence55
Fewer than half of employers under 1,000 staff now use a Big Three PBM
Big Three PBM use among employers with fewer than 1,000 staff fell to 43.8% from 69.7% in a year, a purchaser coalition survey found. For calendar-year plans, federal rebate pass-through attaches at renewal from 2029, so the term signed in the 2027 cycle sets how long a plan waits for it.
Reality
- Evidence58
- Adoption48
- Hype gap+10
- Incentives
- Not scored
- Confidence52
buildOne report1 publisher TJ Parker takes the CEO job at General Medicine as a16z leads its $120M Series B
General Medicine raised $120 million in an a16z-led Series B as PillPack co-founder TJ Parker took over as full-time CEO. The round funds a test of whether one shared, priced catalog can turn medical advice into a booked appointment.
Reality
- Evidence45
- Adoption30
- Hype gap+15
- Incentives70
- Confidence50
Hanmi's Cheaper Obesity Drug Eppe Could Undercut Lilly's Mounjaro More Than Novo's Wegovy
Hanmi Pharmaceutical's Eppe could launch in Korea before year-end at an estimated 150,000 won for four weeks, 45% below Mounjaro's cheapest listing. Lilly won about 85% of the market at a higher price than Wegovy, so Novo, which has cut once already, is the likelier incumbent to cut again.
Reality
- Evidence45
- Adoption
- Not scored
- Hype gap+25
- Incentives
- Not scored
- Confidence40
Retatrutide's top dose cut body weight by a quarter over 80 weeks in a 2,339-adult trial
Retatrutide's 12 mg dose cut body weight 25% over 80 weeks, versus 3.9% on placebo, in a 2,339-adult phase 3 trial in NEJM. Its near-30% two-year figure comes from 532 completers, and because placebo was the only comparator, the trial cannot rank the drug against Ozempic.
Reality
- Evidence65
- Adoption
- Not scored
- Hype gap+20
- Incentives70
- Confidence60
Eli Lilly's 367-person trial found the top dose of tirzepatide plus eloralintide cut body weight 23.3%, against 14.8% on tirzepatide alone. Dropout ran far higher on the combination, so nobody has yet measured how much of that gain holds across everyone prescribed the pair.
Reality
- Evidence60
- Adoption
- Not scored
- Hype gap+30
- Incentives65
- Confidence55
AriBio's Phase 3 readout decides whether Fosun pays another $80 million for AR1001
AriBio's October Phase 3 readout for AR1001 decides whether Fosun Pharma adds $80 million to the $60 million option fee it paid in May. Among the Korean biotech events due that month, it is the one that ties a partner's cash directly to trial data.
Reality
- Evidence40
- Adoption
- Not scored
- Hype gap+20
- Incentives70
- Confidence45